ClinConnect ClinConnect Logo
Search / Trial NCT06927973

Leveraging Exercise Stress Echocardiography for Heart Failure With Preserved Ejection Fraction

Launched by DUKE UNIVERSITY · Apr 7, 2025

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

Stress Echocardiogram

ClinConnect Summary

This clinical trial is exploring a new way to help doctors understand if a patient’s chest pain or shortness of breath is caused by a condition known as heart failure with preserved ejection fraction (HFpEF). Researchers want to see if taking extra images during a stress echocardiogram—a test that uses sound waves to look at the heart while the patient exercises—can provide more information about the heart's function and stiffness. This study aims to improve how doctors diagnose and treat patients experiencing these symptoms.

To participate in this trial, you need to be at least 50 years old and have a medically necessary stress echocardiogram due to shortness of breath or chest pain. However, if you have a known history of HFpEF or certain other heart conditions, you may not be eligible. If you join, you can expect to undergo the stress echocardiogram, where doctors will monitor your heart under exercise conditions and take images to assess its performance. It’s important to know that this study is not currently recruiting participants, but it aims to gather valuable insights to help improve heart health assessments in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Clinically indicated exercise stress echo for the evaluation of exertional dyspnea or chest pain
  • Age ≥50 years
  • Exclusion Criteria:
  • Known history of HFpEF
  • LVEF \<50% on baseline echo study
  • History of hypertrophic cardiomyopathy, amyloidosis, or pulmonary arterial hypertension, severe right ventricular dysfunction and severe valvular disease based on chart review or baseline echo study
  • History of organ transplant (heart, kidney, liver, lungs)
  • Severe pulmonary disease requiring ambulatory oxygen therapy
  • End-stage renal disease requiring long-term renal replacement therapy
  • Decompensated liver disease
  • Conditions that prevent accurate assessment of E/e' ratio (mitral prosthetic valve, severe mitral annular calcification)
  • Plan to use echo contrast agent during stress study (i.e. contrast agent needed for baseline study)
  • Patients from outside Duke health system with no plan for long-term care at Duke

About Duke University

Duke University, a leading academic and research institution located in Durham, North Carolina, is renowned for its commitment to advancing healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, Duke conducts a wide array of clinical trials aimed at developing cutting-edge therapies and improving patient outcomes across various medical fields. The university's Clinical Research Institute provides comprehensive support for trial design, implementation, and regulatory compliance, ensuring that all research adheres to the highest ethical and scientific standards. Duke’s dedication to translating research findings into effective clinical practices underscores its role as a pivotal contributor to the global medical community.

Locations

Durham, North Carolina, United States

Patients applied

0 patients applied

Trial Officials

Marat Fudim, MD

Principal Investigator

Duke University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported